grant
Molecular interplay of HIV Tat, cocaine, and cART in microglial pyroptosis: Role of NLRP3 inflammasome
Organization UNIVERSITY OF NEBRASKA MEDICAL CENTERLocation OMAHA, UNITED STATESPosted 15 Apr 2025Deadline 31 Jan 2030
NIHUS FederalResearch GrantFY202521+ years oldAIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAdultAdult HumanAffectAnti-HIV PositivityAnti-Retroviral AgentsApoptosisApoptosis PathwayApoptosis-Related Cysteine Protease Caspase 1AssayAstrocytesAstrocytusAstrogliaBehaviorBeta Proprotein Interleukin 1BindingBioassayBiological AssayBody TissuesBrain regionCASP-1CASP1CASP1 geneCNS Nervous SystemCaspase-1Caspase-1 GeneCell Communication and SignalingCell DeathCell SignalingCenters for Disease ControlCenters for Disease Control and PreventionCenters for Disease Control and Prevention (U.S.)Central Nervous SystemChronicCocaineCocaine use disorderConfocal MicroscopyDataDevelopmentDiseaseDisorderDrugsELISAEnzyme-Linked Immunosorbent AssayEpidemicExposure toGene InactivationGene SilencingGenerationsGliaGlial CellsGoalsHIVHIV 1 associated neurocognitive disorderHIV InfectionsHIV PositiveHIV PositivityHIV SeroconversionHIV SeropositivityHIV antibody positiveHIV associated neurocognitive deficitHIV associated neurocognitive impairmentHIV associated neurological diseaseHIV associated neurological disorderHIV induced neurocognitive deficitHIV induced neurocognitive impairmentHIV neurocognitive impairmentHIV-1HIV-1 associated neurocognitive deficitHIV-1 associated neurocognitive disorderHIV-1 associated neurocognitive impairmentHIV-IHIV-associated neurocognitive disorderHIV1HTLV-III InfectionsHTLV-III SeroconversionHTLV-III SeropositivityHTLV-III-LAV InfectionsHandHomolog of Drosophila TOLLHortega cellHuman Immunodeficiency Virus Type 1Human Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III InfectionsHuman immunodeficiency virus 1ICE ProteaseIFN-Gamma-Inducing Factor GeneIFN-gamma-Inducing FactorIGIFIGIF GeneIL-1 GammaIL-1 Gamma GeneIL-1 betaIL-1 beta ConvertaseIL-1 beta-Converting EnzymeIL-1 βIL-1-bIL-18IL-18 GeneIL-1BCIL-1b Converting EnzymeIL-1gIL-1g GeneIL-1βIL1-BetaIL1-βIL18IL18 ProteinIL18 geneIL1B ProteinIL1B-ConvertaseIL1BCIL1BCEIL1F2IL1F4IL1F4 GeneIL1βImmunoblottingIn VitroIndividualInflammasomeInflammationInflammatoryInnate Immune ResponseInterferon-Gamma-Inducing Factor GeneInterferon-gamma-Inducing FactorInterleukin 1-B Converting EnzymeInterleukin 1-Beta ConvertaseInterleukin 18 (Interferon-Gamma-Inducing Factor)Interleukin 18 (Interferon-Gamma-Inducing Factor) GeneInterleukin 18 ProproteinInterleukin 18 Proprotein GeneInterleukin 1betaInterleukin-1 Beta Converting EnzymeInterleukin-1 Converting EnzymeInterleukin-1 GammaInterleukin-1 Gamma GeneInterleukin-1 betaInterleukin-18Interleukin-18 PrecursorInterleukin-18 Precursor GeneInterleukin-1βInterventionIntracellular Communication and SignalingInvestigationKnowledgeKolliker's reticulumLAV-HTLV-IIILinkLymphadenopathy-Associated VirusMGC12320MGC12320 GeneMacacaMacaqueMediatingMediatorMedicationMembraneMethodsMiceMice MammalsMicrogliaMolecularMolecular InteractionMurineMusNeuraxisNeurocognitive Impairment in HIVNeurocognitive Impairment in HIV-1NeurogliaNeuroglial CellsNeurologicNeurologicalNeuropathogenesisNon-neuronal cellNonneuronal cellPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPreinterleukin 1 BetaProcessProgrammed Cell DeathProteinsResearchResidualResidual stateRoleShort interfering RNASignal PathwaySignal TransductionSignal Transduction SystemsSignalingSmall Interfering RNAStaining methodStainsSubstance abuse problemTLR proteinTLR4TLR4 geneTestingTissuesToll HomologueToll-Like Receptor Family GeneToll-like receptorsTrans-Acting FactorsTrans-ActivatorsTransactivatorsTranscription ActivatorTranscription CoactivatorTranscription Factor CoactivatorTranscriptional Activator/CoactivatorTransgenic MiceTransgenic OrganismsUnited States Centers for Disease ControlUnited States Centers for Disease Control and PreventionValidationViral Gene ProductsViral Gene ProteinsViral ProteinsVirus-HIVWestern BlottingWestern Immunoblottingabuse of substancesadulthoodanti-retroviralantiretroviral therapyantiretroviral treatmentastrocytic gliabiological signal transductionbrain tissueco-morbidco-morbiditycombinatorialcomorbiditycytokinedevelopmentaldrug/agenteffective therapyeffective treatmentenzyme linked immunoassaygitter cellglial activationglial cell activationhandsin vivoinhibitorinsightmembrane structuremesogliamicroglial cellmicrogliocytemouse modelmurine modelnecrocytosisnerve cementneural inflammationneuro-AIDSneuro-HIVneuroAIDSneuroHIVneuroinflammationneuroinflammatorynew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeutic targetnew therapeuticsnew therapynew therapy approachesnew therapy targetnew treatment approachnew treatment strategynext generation therapeuticsnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy approachnovel therapy targetpathwayperivascular glial cellpharmacologicprotein blottingresponsesiRNAsocial rolesubstance abusesubstance misusetargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic targettherapy adherencetherapy compliancetoll-like receptor 4transcriptional silencingtransgenicvalidationsvirus protein
Description preview
Abstract:
Despite the advent of combination antiretroviral therapy (cART), HIV-associated neurocognitive disorders (or
NeuroHIV) remain prevalent, affecting 30-50% of patients and presenting persistent challenges in managing
neurological complications. Glial cell dysregulation, particularly microglia and astrocytes, drives chronic…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click